Aktienanalyse zu Immunocore Holdings PLC (IMCR)IMCRImmunocore Holdings PLC

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Immunocore Holdings PLC appears to be a good buy right now, given its current price of $29.4, a forward P/E ratio of 23.75, and significant revenue growth of 16% year-over-year in the first half of 2026. The company has a strong cash position of $880 million, which supports its ongoing clinical trials and operational stability. However, the main risk is its reliance on Kimmtrak, which is currently its only marketed product, exposing it to market demand fluctuations.